PT-141 in Houston, for desire — not just function.
PT-141 (bremelanotide) addresses sexual desire through brain pathways — a different solution than PDE-5 inhibitors, for a different problem.
A treatment for desire, not just function.
PT-141 (bremelanotide) is a peptide that works on the brain’s desire pathways rather than on blood flow. Unlike sildenafil or tadalafil, which improve erectile mechanics in men with normal libido, PT-141 directly stimulates the melanocortin receptors involved in sexual arousal and desire.
The brand-name product Vyleesi (bremelanotide) was FDA-approved in 2019 for premenopausal women with hypoactive sexual desire disorder (HSDD). Use in men or in postmenopausal women is off-label; the FDA has not established safety or effectiveness for those uses. The medication is administered as a subcutaneous injection at least 45 minutes before anticipated sexual activity.
When clinically appropriate, your provider may instead prescribe compounded bremelanotide from a licensed pharmacy. Compounded medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality, and compounded bremelanotide is not a generic version of Vyleesi.
What makes PT-141 distinct is that it addresses a different problem than the PDE-5 inhibitors. If erectile mechanics work but the spark isn’t there — if desire has flattened, if interest has disappeared, if intimacy feels disconnected from physical response — PT-141 may be the right conversation. Sildenafil and tadalafil are not desire treatments.
When desire is the missing piece, not mechanics.
PT-141 isn’t for everyone with sexual concerns. It’s specifically useful when the issue is desire rather than function. Here’s how we think about who’s a good candidate.
Erections work, desire doesn’t
Men whose erectile mechanics are intact but who’ve lost interest in sex over the past months or years. Often men on adequate TRT with normal testosterone whose libido still hasn’t returned. Any use in men is off-label and is discussed openly during evaluation.
Considered for: Low desire without ED · Off-label useHSDD — desire that’s gone
Vyleesi is FDA-approved for premenopausal women with hypoactive sexual desire disorder — persistent low desire causing personal distress, not explained by other medical or psychological conditions. Use in postmenopausal women is off-label.
Considered for: Premenopausal HSDD (FDA-approved use)A full evaluation first
For patients whose desire concerns are multifactorial. Your provider evaluates hormonal status first; TRT for men with confirmed deficiency or HRT for women may be considered separately when clinically indicated. Erectile concerns are evaluated on their own.
Considered for: Multifactorial concerns · Individualized evaluationLibido is rarely about libido. Most of the time it’s about everything else.
PT-141 addresses one specific pathway. But desire depends on energy, sleep, hormones, stress, mental health, and relationship dynamics. The patients who do best are the ones who address the whole picture, not just the medication.
The medication can light the spark. The foundations make it sustainable.
Desire depends on more than one pathway, so we look at the broader picture alongside any medication.
- Hormonal foundation — for men, testosterone evaluation (treated only when deficiency is confirmed); for women, appropriate HRT when in the right window
- Sleep and stress — chronic poor sleep and elevated cortisol both crush libido at the source
- Mental and relational context — desire isn’t just biology; stress, depression, anxiety, and relationship dynamics matter
- For erectile mechanics specifically, sildenafil or tadalafil address a different problem
From consultation to first prescription, in real medicine.
PT-141 is a prescription medication that addresses a specific question. The process matches that specificity.
Initial consultation
In person at our Houston clinic. We discuss what’s actually going on — desire vs. mechanics, when changes started, what’s been tried, current medications, hormonal status, and relationship context. We’re honest about whether PT-141 is the right tool or whether the conversation should be about something else first.
Focused workup
Lab work to rule out competing causes — testosterone (men), full hormone panel (women), thyroid, A1c, vitamin D, ferritin. Medication review for known libido-affecting drugs. Cardiovascular screening, since PT-141 can transiently raise blood pressure.
Protocol design
Vyleesi or, where clinically appropriate, compounded bremelanotide prepared by a licensed pharmacy (compounded medications are not FDA-approved). Vyleesi is labeled as a 1.75 mg subcutaneous dose taken at least 45 minutes before anticipated sexual activity, no more than once in 24 hours. Clear instructions on dosing, timing, and what to expect — including realistic expectations about response variability.
First prescription
Your prescription is shipped from the dispensing pharmacy. Includes injection supplies and detailed administration instructions. We’re available for questions about timing, dosing, or any side effects during the early use phase.
Follow-up & adjustment
Brief follow-up to assess response and tolerability. If response is inadequate or side effects are limiting, we adjust. If PT-141 isn’t the right answer, we have an honest conversation about what else might be.
Ready to start the conversation?
A 45-minute consultation with one of our providers. We’ll figure out together whether PT-141 is the right tool for your specific situation, and what else may need to be part of the picture.
What PT-141 can — and can’t — do.
PT-141 may help some patients. It’s also more variable in response than the PDE-5 inhibitors, and the framing matters.
What PT-141 can do
- Improve low desire and related distress in some premenopausal women with HSDD (its FDA-approved use)
- Be used as needed rather than daily
- Be considered off-label in other patients only after evaluation
What PT-141 can’t do
- Produce results in every patient — response is more variable than PDE-5 inhibitors
- Fix relationship issues, depression, or stress-driven libido changes
- Substitute for proper hormonal workup when low T or hormone imbalance is the underlying issue
- Be appropriate for patients with uncontrolled hypertension or cardiovascular concerns
- Avoid all side effects — nausea is the most common, sometimes significant enough to limit use
- Work for everyone — some patients try it and don’t experience a meaningful response
Before you book.
How much does treatment cost?
Consultations start at $49 (see pricing). Medication cost depends on what your provider prescribes and on your insurance coverage. Our clinical service fees cover physician oversight, lab review, and follow-up separately. We’ll discuss specifics during consultation.
How is PT-141 different from sildenafil or tadalafil?
They address completely different problems. Sildenafil and tadalafil are PDE-5 inhibitors that improve blood flow for erections — they help with mechanics. PT-141 works on the brain’s desire pathways through melanocortin receptors — it helps with interest and arousal. Your provider evaluates which concern is present. Bremelanotide is FDA-approved only for premenopausal women with HSDD; use in men is off-label.
What are the side effects?
The most common side effect is nausea, particularly with the first few doses. About 40% of users experience some nausea, though it tends to improve with continued use or with timing adjustments (taking on an empty stomach can make it worse). Other common effects include flushing, headache, and a temporary rise in blood pressure. Some users notice darkening of skin or freckles with frequent use — usually subtle and reversible. Serious side effects are rare.
Is PT-141 FDA-approved?
The brand-name product Vyleesi is FDA-approved for premenopausal women with hypoactive sexual desire disorder. Compounded bremelanotide is not FDA-approved. Use in men or in postmenopausal women is off-label, meaning the FDA has not reviewed its safety or effectiveness for those uses. Any off-label prescribing is a provider decision made after evaluation. We discuss the off-label nature openly during consultation.
How does it actually work?
PT-141 activates melanocortin receptors (specifically MC3R and MC4R) in the central nervous system. These receptors play a role in sexual arousal pathways, regulating both desire and physical sexual response. The mechanism by which it improves desire in premenopausal women with HSDD is not fully understood.
Can I use it with TRT or HRT?
Your provider reviews all current medications, including TRT or HRT, before prescribing. Use alongside hormone therapy, like any use outside the FDA-approved indication, is decided case by case after evaluation.
What if it doesn’t work for me?
Response varies, and not everyone responds to PT-141. If you’ve tried two or three doses without meaningful effect, we have an honest conversation about stopping and considering that PT-141 may not be the right tool for your specific situation. We don’t keep prescribing if it’s not working. Sometimes the answer is addressing a different piece of the picture — sleep, hormones, mental health, or relationship dynamics.
Start with a conversation, not a prescription.
A 45-minute consultation with one of our Houston providers. We’ll figure out what’s actually going on, what’s worth trying, and whether PT-141 fits your specific situation.